Does magnesium sulfate given for prevention of eclampsia affect the outcome of labor?

K. J. Leveno, J. M. Alexander, D. D. McIntire, M. J. Lucas, J. A. Spinnato, M. P. Dombrowski, J. McGregor

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

OBJECTIVE: The purpose of this study was to determine whether magnesium sulfate given for prevention of eclampsia affected labor outcomes compared with phenytoin, which is not known to impede uterine activity when given in anticonvulsant doses. STUDY DESIGN: Secondary analysis was performed of a study of women with pregnancy-induced hypertension who were admitted for delivery and randomly assigned to receive either magnesium sulfate or phenytoin for eclampsia prophylaxis. Nulliparous women with a singleton pregnancy in cephalic presentation at term were selected for analysis in an effort to limit the influence of confounding variables such as preterm birth and malpresentations on labor management and outcomes. Similarly, women who had severe preeclampsia and who received labor epidural analgesia were excluded. RESULTS: A total of 2138 women were randomized to receive magnesium sulfate or phenytoin in the primary study. A total of 905 nulliparous women met the inclusion criteria for this secondary analysis; 480 had been randomized to phenytoin and 425 were given magnesium sulfate. The two groups were similar demographically. Labor outcomes such as (1) oxytocin stimulation, (2) admission-to-delivery intervals, (3) prolonged second-stage labor, (4) forceps delivery, and (5) cesarean delivery were not affected by maternal treatment with magnesium sulfate. CONCLUSION: Compared with phenytoin, magnesium sulfate given for intrapartum treatment of pregnancy induced hypertension does not significantly affect labor outcomes.

Original languageEnglish (US)
Pages (from-to)707-712
Number of pages6
JournalAmerican Journal of Obstetrics and Gynecology
Volume178
Issue number4
DOIs
StatePublished - 1998

Fingerprint

Magnesium Sulfate
Eclampsia
Phenytoin
Pregnancy Induced Hypertension
Second Labor Stage
Epidural Analgesia
Confounding Factors (Epidemiology)
Premature Birth
Oxytocin
Pre-Eclampsia
Surgical Instruments
Anticonvulsants
Head
Mothers
Pregnancy
Therapeutics

Keywords

  • Labor
  • Magnesium sulfate

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Does magnesium sulfate given for prevention of eclampsia affect the outcome of labor? / Leveno, K. J.; Alexander, J. M.; McIntire, D. D.; Lucas, M. J.; Spinnato, J. A.; Dombrowski, M. P.; McGregor, J.

In: American Journal of Obstetrics and Gynecology, Vol. 178, No. 4, 1998, p. 707-712.

Research output: Contribution to journalArticle

Leveno, K. J. ; Alexander, J. M. ; McIntire, D. D. ; Lucas, M. J. ; Spinnato, J. A. ; Dombrowski, M. P. ; McGregor, J. / Does magnesium sulfate given for prevention of eclampsia affect the outcome of labor?. In: American Journal of Obstetrics and Gynecology. 1998 ; Vol. 178, No. 4. pp. 707-712.
@article{843561c320324ecd8555227d515fb552,
title = "Does magnesium sulfate given for prevention of eclampsia affect the outcome of labor?",
abstract = "OBJECTIVE: The purpose of this study was to determine whether magnesium sulfate given for prevention of eclampsia affected labor outcomes compared with phenytoin, which is not known to impede uterine activity when given in anticonvulsant doses. STUDY DESIGN: Secondary analysis was performed of a study of women with pregnancy-induced hypertension who were admitted for delivery and randomly assigned to receive either magnesium sulfate or phenytoin for eclampsia prophylaxis. Nulliparous women with a singleton pregnancy in cephalic presentation at term were selected for analysis in an effort to limit the influence of confounding variables such as preterm birth and malpresentations on labor management and outcomes. Similarly, women who had severe preeclampsia and who received labor epidural analgesia were excluded. RESULTS: A total of 2138 women were randomized to receive magnesium sulfate or phenytoin in the primary study. A total of 905 nulliparous women met the inclusion criteria for this secondary analysis; 480 had been randomized to phenytoin and 425 were given magnesium sulfate. The two groups were similar demographically. Labor outcomes such as (1) oxytocin stimulation, (2) admission-to-delivery intervals, (3) prolonged second-stage labor, (4) forceps delivery, and (5) cesarean delivery were not affected by maternal treatment with magnesium sulfate. CONCLUSION: Compared with phenytoin, magnesium sulfate given for intrapartum treatment of pregnancy induced hypertension does not significantly affect labor outcomes.",
keywords = "Labor, Magnesium sulfate",
author = "Leveno, {K. J.} and Alexander, {J. M.} and McIntire, {D. D.} and Lucas, {M. J.} and Spinnato, {J. A.} and Dombrowski, {M. P.} and J. McGregor",
year = "1998",
doi = "10.1016/S0002-9378(98)70480-6",
language = "English (US)",
volume = "178",
pages = "707--712",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Does magnesium sulfate given for prevention of eclampsia affect the outcome of labor?

AU - Leveno, K. J.

AU - Alexander, J. M.

AU - McIntire, D. D.

AU - Lucas, M. J.

AU - Spinnato, J. A.

AU - Dombrowski, M. P.

AU - McGregor, J.

PY - 1998

Y1 - 1998

N2 - OBJECTIVE: The purpose of this study was to determine whether magnesium sulfate given for prevention of eclampsia affected labor outcomes compared with phenytoin, which is not known to impede uterine activity when given in anticonvulsant doses. STUDY DESIGN: Secondary analysis was performed of a study of women with pregnancy-induced hypertension who were admitted for delivery and randomly assigned to receive either magnesium sulfate or phenytoin for eclampsia prophylaxis. Nulliparous women with a singleton pregnancy in cephalic presentation at term were selected for analysis in an effort to limit the influence of confounding variables such as preterm birth and malpresentations on labor management and outcomes. Similarly, women who had severe preeclampsia and who received labor epidural analgesia were excluded. RESULTS: A total of 2138 women were randomized to receive magnesium sulfate or phenytoin in the primary study. A total of 905 nulliparous women met the inclusion criteria for this secondary analysis; 480 had been randomized to phenytoin and 425 were given magnesium sulfate. The two groups were similar demographically. Labor outcomes such as (1) oxytocin stimulation, (2) admission-to-delivery intervals, (3) prolonged second-stage labor, (4) forceps delivery, and (5) cesarean delivery were not affected by maternal treatment with magnesium sulfate. CONCLUSION: Compared with phenytoin, magnesium sulfate given for intrapartum treatment of pregnancy induced hypertension does not significantly affect labor outcomes.

AB - OBJECTIVE: The purpose of this study was to determine whether magnesium sulfate given for prevention of eclampsia affected labor outcomes compared with phenytoin, which is not known to impede uterine activity when given in anticonvulsant doses. STUDY DESIGN: Secondary analysis was performed of a study of women with pregnancy-induced hypertension who were admitted for delivery and randomly assigned to receive either magnesium sulfate or phenytoin for eclampsia prophylaxis. Nulliparous women with a singleton pregnancy in cephalic presentation at term were selected for analysis in an effort to limit the influence of confounding variables such as preterm birth and malpresentations on labor management and outcomes. Similarly, women who had severe preeclampsia and who received labor epidural analgesia were excluded. RESULTS: A total of 2138 women were randomized to receive magnesium sulfate or phenytoin in the primary study. A total of 905 nulliparous women met the inclusion criteria for this secondary analysis; 480 had been randomized to phenytoin and 425 were given magnesium sulfate. The two groups were similar demographically. Labor outcomes such as (1) oxytocin stimulation, (2) admission-to-delivery intervals, (3) prolonged second-stage labor, (4) forceps delivery, and (5) cesarean delivery were not affected by maternal treatment with magnesium sulfate. CONCLUSION: Compared with phenytoin, magnesium sulfate given for intrapartum treatment of pregnancy induced hypertension does not significantly affect labor outcomes.

KW - Labor

KW - Magnesium sulfate

UR - http://www.scopus.com/inward/record.url?scp=0031957970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031957970&partnerID=8YFLogxK

U2 - 10.1016/S0002-9378(98)70480-6

DO - 10.1016/S0002-9378(98)70480-6

M3 - Article

C2 - 9579432

AN - SCOPUS:0031957970

VL - 178

SP - 707

EP - 712

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 4

ER -